m6A Regulator and Potential Drug Response

General Information of the m6A Regulator (ID: REG00004)
Regulator Name Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1)
Synonyms
hnRNP A2/B1; HNRPA2B1
    Click to Show/Hide
Gene Name HNRNPA2B1
Regulator Type WRITER ERASER READER
Regulator Link Click to View Full Information of This Regulator
Full List of Target Gene(s) of This m6A Regulator and Corresponding Potential Drug Response(s)
ATP-citrate synthase (ACLY)
Bempedoic acid [Approved]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary ATP-citrate synthase (ACLY) is a therapeutic target for Bempedoic acid. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of Bempedoic acid through regulating the expression of ATP-citrate synthase (ACLY). [1], [2]
(-)-hydroxycitrate [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary ATP-citrate synthase (ACLY) is a therapeutic target for (-)-hydroxycitrate. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of (-)-hydroxycitrate through regulating the expression of ATP-citrate synthase (ACLY). [1], [3]
SB-201076 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary ATP-citrate synthase (ACLY) is a therapeutic target for SB-201076. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of SB-201076 through regulating the expression of ATP-citrate synthase (ACLY). [1], [4]
Ephrin type-B receptor 2 (EPHB2)
BVD-523 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for BVD-523. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of BVD-523 through regulating the expression of Ephrin type-B receptor 2 (EPHB2). [5], [6]
SEphB4-HSA [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for SEphB4-HSA. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of SEphB4-HSA through regulating the expression of Ephrin type-B receptor 2 (EPHB2). [5], [7]
KO-947 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for KO-947. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of KO-947 through regulating the expression of Ephrin type-B receptor 2 (EPHB2). [5], [8]
MK-8353 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for MK-8353. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of MK-8353 through regulating the expression of Ephrin type-B receptor 2 (EPHB2). [5], [8]
AMP-PNP [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for AMP-PNP. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of AMP-PNP through regulating the expression of Ephrin type-B receptor 2 (EPHB2). [5], [9]
SNEWIQPRLPQH [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for SNEWIQPRLPQH. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of SNEWIQPRLPQH through regulating the expression of Ephrin type-B receptor 2 (EPHB2). [5], [8]
Extracellular matrix receptor III (CD44)
A-6 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Extracellular matrix receptor III (CD44) is a therapeutic target for A-6. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of A-6 through regulating the expression of Extracellular matrix receptor III (CD44). [10], [11]
SPL-108 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Extracellular matrix receptor III (CD44) is a therapeutic target for SPL-108. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of SPL-108 through regulating the expression of Extracellular matrix receptor III (CD44). [10], [12]
BIWA 4 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Extracellular matrix receptor III (CD44) is a therapeutic target for BIWA 4. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of BIWA 4 through regulating the expression of Extracellular matrix receptor III (CD44). [10], [13]
Bivatuzumab mertansine [Terminated]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Extracellular matrix receptor III (CD44) is a therapeutic target for Bivatuzumab mertansine. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of Bivatuzumab mertansine through regulating the expression of Extracellular matrix receptor III (CD44). [10], [14]
Extracellular signal-regulated kinase 2 (ERK2)
ASTX029 [Phase 1/2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for ASTX029. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of ASTX029 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). [5], [15]
BVD-523 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for BVD-523. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of BVD-523 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). [5], [16]
HH2710 [Phase 1/2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for HH2710. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of HH2710 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). [5], [17]
GDC-0994 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for GDC-0994. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of GDC-0994 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). [5], [8]
JSI-1187 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for JSI-1187. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of JSI-1187 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). [5], [18]
LY3214996 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for LY3214996. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of LY3214996 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). [5], [19]
VAN-10-4-eluting stent [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for VAN-10-4-eluting stent. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of VAN-10-4-eluting stent through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). [5], [20]
COR-D [Preclinical]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for COR-D. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of COR-D through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). [5], [21]
(4-Fluoro-phenyl)-(9-methyl-9H-purin-6-yl)-amine [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for (4-Fluoro-phenyl)-(9-methyl-9H-purin-6-yl)-amine. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of (4-Fluoro-phenyl)-(9-methyl-9H-purin-6-yl)-amine through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). [5], [22]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). [5], [23]
AEZS-131 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for AEZS-131. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of AEZS-131 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). [5], [24]
Bisindolylmaleimide-I [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for Bisindolylmaleimide-I. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of Bisindolylmaleimide-I through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). [5], [25]
BMS 536924 [Preclinical]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for BMS 536924. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of BMS 536924 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). [5], [26]
CI-1040 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for CI-1040. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of CI-1040 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). [5], [27]
DEBROMOHYMENIALDISINE [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for DEBROMOHYMENIALDISINE. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of DEBROMOHYMENIALDISINE through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). [5], [22]
ERK inhibitor III [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for ERK inhibitor III. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of ERK inhibitor III through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). [5], [28]
FR-180204 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for FR-180204. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of FR-180204 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). [5], [29]
KN-62 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for KN-62. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of KN-62 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). [5], [30]
KT-5720 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for KT-5720. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of KT-5720 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). [5], [28]
Phosphonothreonine [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for Phosphonothreonine. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of Phosphonothreonine through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). [5], [31]
RO-316233 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for RO-316233. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of RO-316233 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). [5], [22]
Ro-4396686 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for Ro-4396686. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of Ro-4396686 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). [5], [22]
Ro31-8220 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for Ro31-8220. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of Ro31-8220 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). [5], [32]
SCH772984 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for SCH772984. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of SCH772984 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). [5], [33]
SB220025 [Terminated]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for SB220025. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of SB220025 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). [5], [34]
GTPase KRas (KRAS)
AZD4785 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary GTPase KRas (KRAS) is a therapeutic target for AZD4785. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of AZD4785 through regulating the expression of GTPase KRas (KRAS). [35], [36]
BI 1701963 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary GTPase KRas (KRAS) is a therapeutic target for BI 1701963. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of BI 1701963 through regulating the expression of GTPase KRas (KRAS). [28], [35]
ISIS 6957 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary GTPase KRas (KRAS) is a therapeutic target for ISIS 6957. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of ISIS 6957 through regulating the expression of GTPase KRas (KRAS). [35], [37]
ISIS 6958 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary GTPase KRas (KRAS) is a therapeutic target for ISIS 6958. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of ISIS 6958 through regulating the expression of GTPase KRas (KRAS). [35], [37]
ISIS 7453 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary GTPase KRas (KRAS) is a therapeutic target for ISIS 7453. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of ISIS 7453 through regulating the expression of GTPase KRas (KRAS). [35], [38]
PNT-300 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary GTPase KRas (KRAS) is a therapeutic target for PNT-300. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of PNT-300 through regulating the expression of GTPase KRas (KRAS). [35], [39]
Hepatitis A virus cellular receptor 2 (TIM3)
MBG453 [Phase 3]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Hepatitis A virus cellular receptor 2 (TIM3) is a therapeutic target for MBG453. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of MBG453 through regulating the expression of Hepatitis A virus cellular receptor 2 (TIM3). [10], [40]
BGB-A425 [Phase 1/2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Hepatitis A virus cellular receptor 2 (TIM3) is a therapeutic target for BGB-A425. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of BGB-A425 through regulating the expression of Hepatitis A virus cellular receptor 2 (TIM3). [10], [41]
GSK4069889 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Hepatitis A virus cellular receptor 2 (TIM3) is a therapeutic target for GSK4069889. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of GSK4069889 through regulating the expression of Hepatitis A virus cellular receptor 2 (TIM3). [8], [10]
RO7121661 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Hepatitis A virus cellular receptor 2 (TIM3) is a therapeutic target for RO7121661. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of RO7121661 through regulating the expression of Hepatitis A virus cellular receptor 2 (TIM3). [8], [10]
INCAGN2390 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Hepatitis A virus cellular receptor 2 (TIM3) is a therapeutic target for INCAGN2390. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of INCAGN2390 through regulating the expression of Hepatitis A virus cellular receptor 2 (TIM3). [10], [42]
LY3321367 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Hepatitis A virus cellular receptor 2 (TIM3) is a therapeutic target for LY3321367. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of LY3321367 through regulating the expression of Hepatitis A virus cellular receptor 2 (TIM3). [10], [43]
LY3415244 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Hepatitis A virus cellular receptor 2 (TIM3) is a therapeutic target for LY3415244. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of LY3415244 through regulating the expression of Hepatitis A virus cellular receptor 2 (TIM3). [10], [44]
Sym023 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Hepatitis A virus cellular receptor 2 (TIM3) is a therapeutic target for Sym023. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of Sym023 through regulating the expression of Hepatitis A virus cellular receptor 2 (TIM3). [10], [45]
Leukocyte common antigen (PTPRC)
131I-labelled aCD45 [Phase 3]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Leukocyte common antigen (PTPRC) is a therapeutic target for 131I-labelled aCD45. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of 131I-labelled aCD45 through regulating the expression of Leukocyte common antigen (PTPRC). [10], [46]
Iomab-B [Phase 3]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Leukocyte common antigen (PTPRC) is a therapeutic target for Iomab-B. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of Iomab-B through regulating the expression of Leukocyte common antigen (PTPRC). [10], [47]
[131I]-BC8 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Leukocyte common antigen (PTPRC) is a therapeutic target for [131I]-BC8. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of [131I]-BC8 through regulating the expression of Leukocyte common antigen (PTPRC). [10], [48]
Anti-CD45 mabs [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Leukocyte common antigen (PTPRC) is a therapeutic target for Anti-CD45 mabs. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of Anti-CD45 mabs through regulating the expression of Leukocyte common antigen (PTPRC). [10], [49]
Iomab-ACT [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Leukocyte common antigen (PTPRC) is a therapeutic target for Iomab-ACT. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of Iomab-ACT through regulating the expression of Leukocyte common antigen (PTPRC). [10], [50]
LM-CD45 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Leukocyte common antigen (PTPRC) is a therapeutic target for LM-CD45. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of LM-CD45 through regulating the expression of Leukocyte common antigen (PTPRC). [10], [51]
Asp-BrPmp-Leu [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Leukocyte common antigen (PTPRC) is a therapeutic target for Asp-BrPmp-Leu. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of Asp-BrPmp-Leu through regulating the expression of Leukocyte common antigen (PTPRC). [10], [52]
OX-30 [Terminated]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Leukocyte common antigen (PTPRC) is a therapeutic target for OX-30. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of OX-30 through regulating the expression of Leukocyte common antigen (PTPRC). [10], [53]
microRNA hsa-miR-17 (MIR17)
RGLS4326 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary microRNA hsa-miR-17 (MIR17) is a therapeutic target for RGLS4326. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of RGLS4326 through regulating the expression of microRNA hsa-miR-17 (MIR17). [54], [55]
RAC-alpha serine/threonine-protein kinase (AKT1)
AZD5363 [Phase 3]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for AZD5363. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of AZD5363 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [8], [56]
Enzastaurin [Phase 3]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Enzastaurin. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of Enzastaurin through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [56], [57]
GDC-0068 [Phase 3]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for GDC-0068. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of GDC-0068 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [8], [56]
ARQ 092 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for ARQ 092. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of ARQ 092 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [56], [58]
CI-1033 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for CI-1033. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of CI-1033 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [8], [56]
CMX-2043 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for CMX-2043. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of CMX-2043 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [56], [59]
GSK2110183 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for GSK2110183. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of GSK2110183 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [56], [60]
PTX-200 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for PTX-200. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of PTX-200 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [8], [56]
RX-0201 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for RX-0201. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of RX-0201 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [56], [61]
Triciribine prodrug [Phase 1/2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Triciribine prodrug. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of Triciribine prodrug through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [56], [62]
ARQ 751 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for ARQ 751. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of ARQ 751 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [56], [61]
BMS-754807 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for BMS-754807. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of BMS-754807 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [56], [63]
M2698 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for M2698. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of M2698 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [8], [56]
(Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for (Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of (Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [22], [56]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [23], [56]
4,5,6-trihydroxy-3-methylphthalide [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for 4,5,6-trihydroxy-3-methylphthalide. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of 4,5,6-trihydroxy-3-methylphthalide through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [22], [56]
A-443654 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for A-443654. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of A-443654 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [22], [56]
A-674563 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for A-674563. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of A-674563 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [56], [64]
Akt inhibitor VIII [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Akt inhibitor VIII. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of Akt inhibitor VIII through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [28], [56]
ALM-301 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for ALM-301. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of ALM-301 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [56], [65]
Bisindolylmaleimide-I [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Bisindolylmaleimide-I. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of Bisindolylmaleimide-I through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [56], [66]
BMS 536924 [Preclinical]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for BMS 536924. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of BMS 536924 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [22], [56]
BX-517 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for BX-517. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of BX-517 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [30], [56]
CI-1040 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for CI-1040. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of CI-1040 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [56], [61]
Inositol 1,3,4,5-Tetrakisphosphate [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Inositol 1,3,4,5-Tetrakisphosphate. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of Inositol 1,3,4,5-Tetrakisphosphate through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [56], [67]
KN-62 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for KN-62. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of KN-62 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [56], [66]
Lactoquinomycin [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Lactoquinomycin. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of Lactoquinomycin through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [56], [68]
LD-101 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for LD-101. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of LD-101 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [56], [61]
MYRIOCIN [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for MYRIOCIN. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of MYRIOCIN through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [56], [69]
NU-1001-41 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for NU-1001-41. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of NU-1001-41 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [56], [61]
RO-316233 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for RO-316233. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of RO-316233 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [22], [56]
Ro31-8220 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Ro31-8220. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of Ro31-8220 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [56], [70]
SB-747651A [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for SB-747651A. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of SB-747651A through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [29], [56]
STAUROSPORINONE [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for STAUROSPORINONE. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of STAUROSPORINONE through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [56], [69]
VLI-27 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for VLI-27. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of VLI-27 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [56], [61]
Squalestatin 1 [Terminated]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Squalestatin 1. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of Squalestatin 1 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [8], [56]
RAC-gamma serine/threonine-protein kinase (AKT3)
AZD5363 [Phase 3]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-gamma serine/threonine-protein kinase (AKT3) is a therapeutic target for AZD5363. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of AZD5363 through regulating the expression of RAC-gamma serine/threonine-protein kinase (AKT3). [71], [72]
ARQ 092 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-gamma serine/threonine-protein kinase (AKT3) is a therapeutic target for ARQ 092. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of ARQ 092 through regulating the expression of RAC-gamma serine/threonine-protein kinase (AKT3). [71], [73]
GSK2141795 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-gamma serine/threonine-protein kinase (AKT3) is a therapeutic target for GSK2141795. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of GSK2141795 through regulating the expression of RAC-gamma serine/threonine-protein kinase (AKT3). [71], [74]
MK-2206 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-gamma serine/threonine-protein kinase (AKT3) is a therapeutic target for MK-2206. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of MK-2206 through regulating the expression of RAC-gamma serine/threonine-protein kinase (AKT3). [71], [75]
BAY1125976 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-gamma serine/threonine-protein kinase (AKT3) is a therapeutic target for BAY1125976. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of BAY1125976 through regulating the expression of RAC-gamma serine/threonine-protein kinase (AKT3). [71], [76]
GSK690693 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-gamma serine/threonine-protein kinase (AKT3) is a therapeutic target for GSK690693. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of GSK690693 through regulating the expression of RAC-gamma serine/threonine-protein kinase (AKT3). [71], [77]
LY2780301 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-gamma serine/threonine-protein kinase (AKT3) is a therapeutic target for LY2780301. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of LY2780301 through regulating the expression of RAC-gamma serine/threonine-protein kinase (AKT3). [71], [78]
LYS-6KAKT1 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-gamma serine/threonine-protein kinase (AKT3) is a therapeutic target for LYS-6KAKT1. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of LYS-6KAKT1 through regulating the expression of RAC-gamma serine/threonine-protein kinase (AKT3). [71], [79]
M2698 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-gamma serine/threonine-protein kinase (AKT3) is a therapeutic target for M2698. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of M2698 through regulating the expression of RAC-gamma serine/threonine-protein kinase (AKT3). [71], [78]
SR13668 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-gamma serine/threonine-protein kinase (AKT3) is a therapeutic target for SR13668. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of SR13668 through regulating the expression of RAC-gamma serine/threonine-protein kinase (AKT3). [71], [80]
TCN-P [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-gamma serine/threonine-protein kinase (AKT3) is a therapeutic target for TCN-P. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of TCN-P through regulating the expression of RAC-gamma serine/threonine-protein kinase (AKT3). [71], [81]
XL418 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-gamma serine/threonine-protein kinase (AKT3) is a therapeutic target for XL418. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of XL418 through regulating the expression of RAC-gamma serine/threonine-protein kinase (AKT3). [8], [71]
Akt inhibitor VIII [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-gamma serine/threonine-protein kinase (AKT3) is a therapeutic target for Akt inhibitor VIII. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of Akt inhibitor VIII through regulating the expression of RAC-gamma serine/threonine-protein kinase (AKT3). [71], [82]
ISC-4 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-gamma serine/threonine-protein kinase (AKT3) is a therapeutic target for ISC-4. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of ISC-4 through regulating the expression of RAC-gamma serine/threonine-protein kinase (AKT3). [64], [71]
ISIS 29112 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-gamma serine/threonine-protein kinase (AKT3) is a therapeutic target for ISIS 29112. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of ISIS 29112 through regulating the expression of RAC-gamma serine/threonine-protein kinase (AKT3). [71], [83]
ISIS 29135 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-gamma serine/threonine-protein kinase (AKT3) is a therapeutic target for ISIS 29135. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of ISIS 29135 through regulating the expression of RAC-gamma serine/threonine-protein kinase (AKT3). [71], [83]
ISIS 29136 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-gamma serine/threonine-protein kinase (AKT3) is a therapeutic target for ISIS 29136. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of ISIS 29136 through regulating the expression of RAC-gamma serine/threonine-protein kinase (AKT3). [71], [83]
ISIS 29137 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-gamma serine/threonine-protein kinase (AKT3) is a therapeutic target for ISIS 29137. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of ISIS 29137 through regulating the expression of RAC-gamma serine/threonine-protein kinase (AKT3). [71], [83]
ISIS 29138 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-gamma serine/threonine-protein kinase (AKT3) is a therapeutic target for ISIS 29138. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of ISIS 29138 through regulating the expression of RAC-gamma serine/threonine-protein kinase (AKT3). [71], [83]
ISIS 29139 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-gamma serine/threonine-protein kinase (AKT3) is a therapeutic target for ISIS 29139. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of ISIS 29139 through regulating the expression of RAC-gamma serine/threonine-protein kinase (AKT3). [71], [83]
ISIS 29154 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-gamma serine/threonine-protein kinase (AKT3) is a therapeutic target for ISIS 29154. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of ISIS 29154 through regulating the expression of RAC-gamma serine/threonine-protein kinase (AKT3). [71], [83]
ISIS 29155 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-gamma serine/threonine-protein kinase (AKT3) is a therapeutic target for ISIS 29155. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of ISIS 29155 through regulating the expression of RAC-gamma serine/threonine-protein kinase (AKT3). [71], [83]
ISIS 29156 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-gamma serine/threonine-protein kinase (AKT3) is a therapeutic target for ISIS 29156. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of ISIS 29156 through regulating the expression of RAC-gamma serine/threonine-protein kinase (AKT3). [71], [83]
ISIS 29159 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-gamma serine/threonine-protein kinase (AKT3) is a therapeutic target for ISIS 29159. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of ISIS 29159 through regulating the expression of RAC-gamma serine/threonine-protein kinase (AKT3). [71], [83]
ISIS 29160 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-gamma serine/threonine-protein kinase (AKT3) is a therapeutic target for ISIS 29160. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of ISIS 29160 through regulating the expression of RAC-gamma serine/threonine-protein kinase (AKT3). [71], [83]
ISIS 29161 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-gamma serine/threonine-protein kinase (AKT3) is a therapeutic target for ISIS 29161. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of ISIS 29161 through regulating the expression of RAC-gamma serine/threonine-protein kinase (AKT3). [71], [83]
ISIS 29176 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-gamma serine/threonine-protein kinase (AKT3) is a therapeutic target for ISIS 29176. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of ISIS 29176 through regulating the expression of RAC-gamma serine/threonine-protein kinase (AKT3). [71], [83]
ISIS 29177 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-gamma serine/threonine-protein kinase (AKT3) is a therapeutic target for ISIS 29177. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of ISIS 29177 through regulating the expression of RAC-gamma serine/threonine-protein kinase (AKT3). [71], [83]
ISIS 29178 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-gamma serine/threonine-protein kinase (AKT3) is a therapeutic target for ISIS 29178. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of ISIS 29178 through regulating the expression of RAC-gamma serine/threonine-protein kinase (AKT3). [71], [83]
ISIS 29200 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-gamma serine/threonine-protein kinase (AKT3) is a therapeutic target for ISIS 29200. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of ISIS 29200 through regulating the expression of RAC-gamma serine/threonine-protein kinase (AKT3). [71], [83]
ISIS 29201 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-gamma serine/threonine-protein kinase (AKT3) is a therapeutic target for ISIS 29201. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of ISIS 29201 through regulating the expression of RAC-gamma serine/threonine-protein kinase (AKT3). [71], [83]
ISIS 29202 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-gamma serine/threonine-protein kinase (AKT3) is a therapeutic target for ISIS 29202. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of ISIS 29202 through regulating the expression of RAC-gamma serine/threonine-protein kinase (AKT3). [68], [71]
SB-747651A [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary RAC-gamma serine/threonine-protein kinase (AKT3) is a therapeutic target for SB-747651A. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of SB-747651A through regulating the expression of RAC-gamma serine/threonine-protein kinase (AKT3). [71], [84]
Transforming growth factor beta 1 (TGFB1)
Pirfenidone [Approved]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Transforming growth factor beta 1 (TGFB1) is a therapeutic target for Pirfenidone. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of Pirfenidone through regulating the expression of Transforming growth factor beta 1 (TGFB1). [85], [86]
LY2157299 [Phase 2/3]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Transforming growth factor beta 1 (TGFB1) is a therapeutic target for LY2157299. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of LY2157299 through regulating the expression of Transforming growth factor beta 1 (TGFB1). [85], [87]
TG-C [Phase 3]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Transforming growth factor beta 1 (TGFB1) is a therapeutic target for TG-C. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of TG-C through regulating the expression of Transforming growth factor beta 1 (TGFB1). [85], [88]
Disitertide [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Transforming growth factor beta 1 (TGFB1) is a therapeutic target for Disitertide. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of Disitertide through regulating the expression of Transforming growth factor beta 1 (TGFB1). [8], [85]
ABBV-151 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Transforming growth factor beta 1 (TGFB1) is a therapeutic target for ABBV-151. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of ABBV-151 through regulating the expression of Transforming growth factor beta 1 (TGFB1). [85], [89]
SRK-181 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Transforming growth factor beta 1 (TGFB1) is a therapeutic target for SRK-181. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of SRK-181 through regulating the expression of Transforming growth factor beta 1 (TGFB1). [85], [90]
ART-144 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Transforming growth factor beta 1 (TGFB1) is a therapeutic target for ART-144. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of ART-144 through regulating the expression of Transforming growth factor beta 1 (TGFB1). [85], [91]
Mannose phosphate [Discontinued in Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Transforming growth factor beta 1 (TGFB1) is a therapeutic target for Mannose phosphate. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of Mannose phosphate through regulating the expression of Transforming growth factor beta 1 (TGFB1). [85], [92]
References
Ref 1 m(6)A Reader HNRNPA2B1 Promotes Esophageal Cancer Progression via Up-Regulation of ACLY and ACC1. Front Oncol. 2020 Sep 29;10:553045. doi: 10.3389/fonc.2020.553045. eCollection 2020.
Ref 2 A liver-selective LXR inverse agonist that suppresses hepatic steatosis. ACS Chem Biol. 2013 Mar 15;8(3):559-67. doi: 10.1021/cb300541g. Epub 2012 Dec 27.
Ref 3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
Ref 4 2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3208-11. doi: 10.1016/j.bmcl.2007.03.017. Epub 2007 Mar 12.
Ref 5 hnRNPA2B1 Promotes Colon Cancer Progression via the MAPK Pathway. Front Genet. 2021 Sep 22;12:666451. doi: 10.3389/fgene.2021.666451. eCollection 2021.
Ref 6 National Cancer Institute Drug Dictionary (drug name SEphB4-HSA).
Ref 7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
Ref 8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 9 Three-dimensional structure of the EphB2 receptor in complex with an antagonistic peptide reveals a novel mode of inhibition. J Biol Chem. 2007 Dec 14;282(50):36505-13. doi: 10.1074/jbc.M706340200. Epub 2007 Sep 26.
Ref 10 Roles of the m(6)A Modification of RNA in the Glioblastoma Microenvironment as Revealed by Single-Cell Analyses. Front Immunol. 2022 Apr 26;13:798583. doi: 10.3389/fimmu.2022.798583. eCollection 2022.
Ref 11 Clinical pipeline report, company report or official report of Splash Pharmaceuticals.
Ref 12 UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst. 1996 Jul 17;88(14):956-65. doi: 10.1093/jnci/88.14.956.
Ref 13 Modulation of CD44 Activity by A6-Peptide. Front Immunol. 2015 Mar 30;6:135. doi: 10.3389/fimmu.2015.00135. eCollection 2015.
Ref 14 A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6064-72. doi: 10.1158/1078-0432.CCR-06-0910.
Ref 15 DOI: 10.1158/1538-7445.AM2015-4693
Ref 16 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1804).
Ref 17 Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
Ref 18 Clinical pipeline report, company report or official report of HaiHe Biopharma.
Ref 19 National Cancer Institute Drug Dictionary (drug name JSI1187).
Ref 20 ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
Ref 21 Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95. doi: 10.2337/diabetes.52.3.588.
Ref 22 Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. doi: 10.1042/0264-6021:3510095.
Ref 23 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9. doi: 10.1021/jm0605740.
Ref 24 Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 2013 Jul;3(7):742-50. doi: 10.1158/2159-8290.CD-13-0070. Epub 2013 Apr 24.
Ref 25 Potent inhibition of checkpoint kinase activity by a hymenialdisine-derived indoloazepine. Bioorg Med Chem Lett. 2004 Aug 16;14(16):4319-21. doi: 10.1016/j.bmcl.2004.05.079.
Ref 26 Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22. doi: 10.1021/jm0408767.
Ref 27 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1495).
Ref 28 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
Ref 29 Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity. J Med Chem. 2005 Sep 8;48(18):5639-43. doi: 10.1021/jm050392q.
Ref 30 Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47. doi: 10.1021/jm049854a.
Ref 31 Crystal structure of human ERK2 complexed with a pyrazolo[3,4-c]pyridazine derivative. Bioorg Med Chem Lett. 2006 Jan 1;16(1):55-8. doi: 10.1016/j.bmcl.2005.09.055. Epub 2005 Oct 18.
Ref 32 Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3. doi: 10.1016/j.bmcl.2005.12.092. Epub 2006 Feb 3.
Ref 33 Characterization of ATP-independent ERK inhibitors identified through in silico analysis of the active ERK2 structure. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6281-7. doi: 10.1016/j.bmcl.2006.09.038. Epub 2006 Sep 26.
Ref 34 Corchorusin-D directed apoptosis of K562 cells occurs through activation of mitochondrial and death receptor pathways and suppression of AKT/PKB pathway. Cell Physiol Biochem. 2012;30(4):915-26. doi: 10.1159/000341469. Epub 2012 Sep 12.
Ref 35 The UCA1/KRAS axis promotes human pancreatic ductal adenocarcinoma stem cell properties and tumor growth. Am J Cancer Res. 2019 Mar 1;9(3):496-510. eCollection 2019.
Ref 36 Clinical pipeline report, company report or official report of Boehringer Ingelheim.
Ref 37 US patent application no. 5,965,722, Antisense inhibition of ras gene with chimeric and alternating oligonucleotides.
Ref 38 Diversity-oriented synthesis: exploring the intersections between chemistry and biology. Nat Chem Biol. 2005 Jul;1(2):74-84. doi: 10.1038/nchembio0705-74.
Ref 39 Antisense oligonucleotides demonstrate a dominant role of c-Ki-RAS proteins in regulating the proliferation of diploid human fibroblasts. J Biol Chem. 1996 Nov 8;271(45):28259-65. doi: 10.1074/jbc.271.45.28259.
Ref 40 Synthesis and biological evaluation of substrate-based inhibitors of 6-phosphogluconate dehydrogenase as potential drugs against African trypanosomiasis. Bioorg Med Chem. 2003 Jul 17;11(14):3205-14. doi: 10.1016/s0968-0896(03)00191-3.
Ref 41 Clinical pipeline report, company report or official report of GlaxoSmithKline.
Ref 42 Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors. Clin Cancer Res. 2021 May 15;27(10):2773-2781. doi: 10.1158/1078-0432.CCR-20-3716. Epub 2021 Jan 13.
Ref 43 Clinical pipeline report, company report or official report of Symphogen.
Ref 44 Clinical pipeline report, company report or official report of BeiGene.
Ref 45 Clinical pipeline report, company report or official report of Agenus.
Ref 46 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 728).
Ref 47 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood. 2006 Mar 1;107(5):2184-91. doi: 10.1182/blood-2005-06-2317. Epub 2005 Oct 27.
Ref 48 Clinical pipeline report, company report or official report of Actinium Pharmaceuticals.
Ref 49 Clinical pipeline report, company report or official report of Actinium Pharmaceuticals.
Ref 50 Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood. 1995 Feb 15;85(4):1122-31.
Ref 51 CD45 monoclonal antibody-mediated cytolysis of human NK and T lymphoma cells. Haematologica. 2006 Jul;91(7):886-94.
Ref 52 CD45 / PTPRC Antibody, Biotin conjugate (OX-30).
Ref 53 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002932)
Ref 54 HNRNPA2B1 Is a Mediator of m(6)A-Dependent Nuclear RNA Processing Events. Cell. 2015 Sep 10;162(6):1299-308. doi: 10.1016/j.cell.2015.08.011. Epub 2015 Aug 27.
Ref 55 NRF2 Regulation Processes as a Source of Potential Drug Targets against Neurodegenerative Diseases. Biomolecules. 2020 Jun 14;10(6):904. doi: 10.3390/biom10060904.
Ref 56 HNRNPA2B1 regulates tamoxifen- and fulvestrant-sensitivity and hallmarks of endocrine resistance in breast cancer cells. Cancer Lett. 2021 Oct 10;518:152-168. doi: 10.1016/j.canlet.2021.07.015. Epub 2021 Jul 14.
Ref 57 Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development. J Med Chem. 2009 Dec 10;52(23):7360-3. doi: 10.1021/jm900786r.
Ref 58 CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
Ref 59 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
Ref 60 Pre-clinical and Clinical Safety Studies of CMX-2043: a cytoprotective lipoic acid analogue for ischaemia-reperfusion injury. Basic Clin Pharmacol Toxicol. 2014 Nov;115(5):456-64. doi: 10.1111/bcpt.12254. Epub 2014 May 16.
Ref 61 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
Ref 62 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 63 Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015). Expert Opin Ther Pat. 2017 Jul;27(7):753-761. doi: 10.1080/13543776.2017.1325465. Epub 2017 May 5.
Ref 64 2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles. Bioorg Med Chem Lett. 2010 Jan 15;20(2):679-83. doi: 10.1016/j.bmcl.2009.11.060. Epub 2009 Nov 20.
Ref 65 Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011 Oct 30;29(11):1046-51. doi: 10.1038/nbt.1990.
Ref 66 Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3814-8. doi: 10.1016/j.bmcl.2007.04.071. Epub 2007 Apr 27.
Ref 67 The PI3K/Akt pathway as a target in the treatment of hematologic malignancies. Anticancer Agents Med Chem. 2009 Jun;9(5):550-9. doi: 10.2174/187152009788451851.
Ref 68 Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase. J Med Chem. 2008 Sep 25;51(18):5663-79. doi: 10.1021/jm8004527.
Ref 69 Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation. Nat Chem Biol. 2008 Sep;4(9):538-47. doi: 10.1038/nchembio.103. Epub 2008 Jul 20.
Ref 70 A phthalide with in vitro growth inhibitory activity from an oidiodendron strain. J Nat Prod. 2004 Dec;67(12):2086-9. doi: 10.1021/np040123n.
Ref 71 HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA. J Hematol Oncol. 2021 Apr 1;14(1):54. doi: 10.1186/s13045-021-01066-6.
Ref 72 Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase. Bioorg Med Chem Lett. 2013 Feb 15;23(4):1051-5. doi: 10.1016/j.bmcl.2012.12.028. Epub 2012 Dec 20.
Ref 73 Inhibiting the akt pathway in cancer treatment: three leading candidates. P T. 2011 Apr;36(4):225-7.
Ref 74 First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol. 2011 Dec 10;29(35):4688-95. doi: 10.1200/JCO.2011.35.5263. Epub 2011 Oct 24.
Ref 75 The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood. 2014 Oct 2;124(14):2190-5. doi: 10.1182/blood-2014-03-559963. Epub 2014 Jul 29.
Ref 76 Targeting the phosphoinositide 3-kinase (PI3K) pathway in cancer
Ref 77 A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. Invest New Drugs. 2015 Jun;33(3):710-9. doi: 10.1007/s10637-015-0241-7. Epub 2015 Apr 24.
Ref 78 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics. 2005 Aug;86(2):127-41. doi: 10.1016/j.ygeno.2005.04.008.
Ref 79 Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668. Cancer Prev Res (Phila). 2011 Mar;4(3):347-53. doi: 10.1158/1940-6207.CAPR-10-0313.
Ref 80 Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. Invest New Drugs. 2011 Dec;29(6):1381-9. doi: 10.1007/s10637-010-9479-2. Epub 2010 Jul 20.
Ref 81 Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res. 2008 Apr 1;68(7):2366-74. doi: 10.1158/0008-5472.CAN-07-5783.
Ref 82 DOI: 10.1016/S1359-6349(10)71767-5
Ref 83 US patent application no. 6,187,586, Antisense modulation of AKT-3 expression.
Ref 84 US patent application no. 6,395,545, Antisense modulation of inhibitor-kappa B kinase-alpha expression.
Ref 85 HNRNPA2B1, as a m(6)A Reader, Promotes Tumorigenesis and Metastasis of Oral Squamous Cell Carcinoma. Front Oncol. 2021 Sep 23;11:716921. doi: 10.3389/fonc.2021.716921. eCollection 2021.
Ref 86 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 87 Clinical pipeline report, company report or official report of Tissue Gene, Inc.
Ref 88 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
Ref 89 Perspectives of TGF-beta inhibition in pancreatic and hepatocellular carcinomas. Oncotarget. 2014 January; 5(1): 78-94.
Ref 90 Clinical pipeline report, company report or official report of AbbVie.
Ref 91 The mannose-6-phosphate analogue, PXS64, inhibits fibrosis via TGF-Beta1 pathway in human lung fibroblasts. Immunol Lett. 2015 Jun;165(2):90-101. doi: 10.1016/j.imlet.2015.04.003. Epub 2015 Apr 27.
Ref 92 Clinical pipeline report, company report or official report of Scholar Rock.